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The objectives of this article are to review the diagnosis and management of acute nonrenal reactions to iodinated contrast media. We will
begin by discussing the types of contrast media and their correlative rates of reaction. The mechanism of contrast reactions, predisposing risk
factors, and preventative measures will then be discussed. The remainder of the article will review the assessment of potential reactions,
initial management, and treatment algorithms for specific reactions.Resume
Cet article vise a etudier le diagnostic et la prise en charge des reactions extrarenales aigu€es aux produits de contraste iodes. Nous
traiterons d’abord des types d’agents de contraste et de leur taux de reaction respectif. Ensuite, nous aborderons les mecanismes de reaction
aux agents de contraste, les facteurs de risque predisposants et les mesures preventives. Enfin, nous examinerons l’evaluation des reactions
potentielles, la prise en charge initiale et les algorithmes de traitement des reactions particulieres.
 2013 Canadian Association of Radiologists. All rights reserved.
Key Words: Acute reactions; Iodinated contrastAcute contrast reactions may present with a wide spectrum
of symptoms and can affect multiple organ systems. Severe
reactions may progress to life-threatening emergencies if not
managed appropriately and efficiently. It is imperative that
radiologists and medical personnel who administer intravas-
cular contrast are aware of these implications and are prepared
to diagnose and treat acute reactions. In this article, we discuss
the diagnosis and management of acute nonrenal iodinated
contrast reactions. We also review the incidence, pathogen-
esis, risk factors, and prevention of such reactions.
High-Osmolar vs Low-Osmolar Contrast Media
The osmolality of a particular contrast agent is determined
by the number of osmotically active particles formed when it
dissolves in solution. Ionic high-osmolal contrast media
(HOCM) agents are ionic salts that dissociate into a cation
and anion in solution [1,2]. Nonionic low-osmolal contrast* Address for correspondence: Ramesh S. Iyer, MD, Department of
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http://dx.doi.org/10.1016/j.carj.2011.12.014media (LOCM) agents do not dissociate into separate parti-
cles. Therefore, LOCMs have approximately one-half of the
osmolality of HOCMs [2]. The hyperosmolality of contrast
agents is believed to be at least partly responsible for several
subjective and objective adverse effects, including pain,
endothelial damage, thrombosis, and bradycardia [3,4].
The overall incidence of adverse contrast reactions is
significantly lower for nonionic LOCM agents than HOCM
[5e7]. The European Society of Urogenital Radiology
reports that mild adverse reactions are encountered in as
many as 15% of patients after intravenous HOCM (1000-
2000 mOsm/kg H2O), compared with 3% of patients after
intravenous LOCM (500-1000 mOsm/kg H2O) [5e7]. In
1990, Katayama et al [8] performed a large-scale (337,647
cases) prospective clinical study that compared the incidence
of adverse contrast reactions in ionic HOCM vs nonionic
LOCM. The overall prevalence of adverse reactions was
12.66% in the HOCM group and 3.13% in the LOCM group.
Severe reactions occurred in 0.22% in the former group
compared with 0.04% in the latter group [8]. Thus, the
incidence of contrast reactions with LOCM is lower by
a factor of 5 for mild reactions and by a factor of 10 for
severe reactions, compared with HOCM [6,9].ll rights reserved.
Table 2
Recommended premedication protocols for patients at high-risk for acute
contrast reactionsa
Lasser protocol: 32 mg oral methylprednisolone 12 h and 2 h before
examination.
Greenberger protocol: 50 mg oral prednisone 13 h, 7 h, and 1 h before
examination; 50 mg oral diphenhydramine 1 h before examination.
a From Ref. 1.
Table 1
Predisposing risk factors for acute adverse reactions to intravascular contrast
mediaa
History of severe adverse reaction
Asthma
History of allergic tendencies (eg, troublesome hay fever)
Dehydration
Heart disease
Pre-existing renal disease
Hematologic conditions (eg, sickle cell anemia, polycythemia, multiple
myeloma)
b-Blocker therapy
Interleukin-2 therapy
Mastocytosis
Malignant tumours
a From Ref. 16.
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significantly over time. According to the study by Katayama
et al [8], the risk of a fatal reaction after injection of LOCM
is approximately 1 in 170,000 as of 1990. The reduction of
fatal reactions from 1 in 30,000 to 1 in 170,000 over the
preceding 30 years has been attributed to both increasing use
of LOCMs as well as improved training among radiologists
and personnel to diagnose and treat acute events [10].
Mechanism of Contrast Reaction
The exact pathogenesis for contrast-induced anaphylactoid
reactions is still unknown, but several theories have been re-
ported. Elliot Lasser has proposed that the contrast-containing
molecule does not bind directly to an antigen-specific site
[11]. Instead, the large molecule overloads antigen-binding
sites on immunoglobulin E proteins situated on basophils
and mast cells. Because this immunoglobulin binding is
nonspecific, the resultant contrast reaction depends on the
quantity of circulating immunoglobulin E and mast cells at the
time of contrast administration. This binding also varies with
the type of contrast media administered. This theory of
nonspecific immunoglobulin binding on inflammatory cells
may explain why patients with a strong allergy history are
more prone to contrast reactions and why prior contrast
exposure is not a requisite for a severe anaphylactoid reaction
to occur [10,11].
Activation of factor XII (Hageman factor) of the clotting
system, with subsequent activation of the kinin system and
production of bradykinin, may also contribute to the patho-
mechanism for anaphylactoid contrast reactions. Bradykinin
may cause vasodilation, bronchospasm, and increased
vascular permeability [12e15]. Bradykinin may also activate
the cyclooxygenase and lipoxygenase inflammatory path-
ways and the production of prostaglandin and leukotrienes
[10,12]. Patients with asthma or allergy have increased levels
of factor XII products, which likely renders them more
susceptible to adverse contrast reactions [14,15].
Predisposing Risk Factors
The predisposing risk factors are shown in Table 1. The
strongest risk factors for acute adverse contrast reactions are
history of severe reaction and asthma. There is a 6-fold
increase in adverse reactions to both ionic and nonionic
contrast media in patients with a history of severe adverse
reaction [12]. Recurrent adverse reaction occurs in 17%-35%
of patients with a history of adverse reaction when HOCM
agents are used; use of LOCM agents reduces this risk of
recurrent reaction to 5% [16]. Asthma increases the risk of
adverse reactions by 10-fold when HOCMs are used and by
6-fold when LOCMs are used [12,16].
Patients who are debilitated or medically unstable are
inherently at increased risk for an adverse reaction due to the
chemotoxic effects of intravascular contrast media [17].
Patients with generalized allergic tendencies or diatheses,
including troublesome hay fever, are also at increased riskfor acute reactions [12,17]. Patients on b-adrenergic blockers
and interleukin 2 are more susceptible to contrast reactions
[18e20]. Malignant tumours may also increase the incidence
of anaphylactoid reactions, possibly due to increased hista-
mine release in patients with tumour [12,21].
Prevention
If contrast must be administered, then the best treatment
for acute reactions is prevention (Table 2). If the patient has
previously had a severe adverse reaction to intravascular
contrast, then the necessity for contrast in the upcoming
examination should be scrutinized by the radiologist. Non-
contrast examinations may suffice in many cases. If iodinated
contrast is deemed essential, then nonionic LOCM should be
administered.
Several researchers have demonstrated that premedication
with corticosteroids reduces the incidence of adverse reactions
to intravascular contrast media. In a 1987 randomized
controlled trial by Lasser et al [22], 2 doses of oral cortico-
steroids (32 mg methylprednisolone) 12 hours and 2 hours
before ionic contrast administration reduced the risk of all
adverse reactions from 9% to 6.4%. The frequency of severe
reactions was also reduced from 2% to 1.2% [22]. In 1984,
Greenberger et al [23] showed that a premedication regimen of
50 mg of oral prednisolone at 13 hours, 7 hours, and 1 hour
before injection of the contrast material and 50 mg of oral
diphenhydramine at 1 hour before ionic contrast media
injection reduced the rate of adverse reactions from 9% to 7%
in those patients with previous reactions. Antihistamines are
often incorporated into premedication regimens because of
their generalized anti-inflammatory effects. Results of studies
Table 3
Classification of severity of adverse contrast reactionsa
Mild Moderate Severe
Nausea and/or vomiting, urticaria Symptomatic urticaria, mild bronchospasm,
vasovagal reaction, tachycardia, diffuse erythema
Cardiovascular collapse, moderate or severe bronchospasm,
laryngeal oedema, loss of consciousness, seizure
a From Ref. 25.
Table 4
First-line medications and equipment for areas where intravascular contrast
is administereda
Oxygen
Epinephrine (subcutaneous, intramuscular, and/or intravenous)
Antihistamine (oral and/or intravenous)
Atropine
b-Agonist metered dose inhaler
Intravenous fluid: normal saline solution or lactated Ringer’s solution
Anticonvulsant (eg, diazepam)
Sphygmomanometer
Non-rebreather mask
a From Ref. 5.
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corticosteroids, have not been proven to effectively prevent
adverse reactions [24].
Types of Contrast Reactions
Types of contrast reactions are shown in Table 3. Acute
reactions to contrast media are defined as adverse events that
occur within 60 minutes of injection of contrast media [5].
Reactions may be categorized as mild, moderate, or severe.
Mild reactions include flushing, nausea, vomiting, pruritus,
headache, and mild urticaria. These reaction are usually brief
in duration and self-limiting and require no specific treat-
ment. Moderate reactions include bronchospasm, moderate
urticaria, and vasovagal reactions. These conditions respond
readily to appropriate treatment. Severe reactions include
laryngeal oedema, severe bronchospasm, seizure, and
cardiovascular collapse. These entities are life-threatening
and require rapid intervention [5,17,25].
The majority of adverse reactions to intravascular contrast
agents are mild. A 2009 study by Hunt et al [25] retro-
spectively reviewed 456,930 contrast doses (298,491 low-
osmolar iodinated, 158,439 gadolinium) administered over
the 4-year study period. They reported that the most common
adverse effects were hives (275 [52.5% of all adverse
effects]) and nausea (92 [17.6%]). These reactions were
typically managed either with observation or diphenhydra-
mine [25].
It has been reported that 94%-100 % of severe and fatal
reactions to intravascular contrast media occur within 20
minutes after contrast administration [26,27]. For this reason,
the European Society of Urogenital Radiology recommends
that patients be observed for 20-30 minutes in the radiology
department after contrast medium injection [27].
Basics for Initial Assessment and Management
Bush and Segal [10] assert that, when a contrast reaction
is recognized and managed earlier, less medication is
required to achieve a better outcome. The goals of the
treating radiologist and assisting personnel should include
prompt recognition of a possible reaction, early patient
assessment, diagnosis of reaction type, and rapid initiation of
appropriate therapy. In areas where intravascular contrast is
administered, first-line therapy and equipment should be
stocked and accessible at all times. Recommended medica-
tions and equipment that should be available in such areas
are listed in Table 4.
Basic management principles for contrast reactions
include the following [8,10,17]:Initial Evaluation and Management for Acute Contrast
Reactions
1. Call for rapid response team (eg, 911).
2. Assess the patient (eg, vital signs).
3. Ensure or establish an airway.
4. Supplemental oxygen: oxygen by mask at high rate (6-10
L/min).
5. Obtain intravenous access for rapid fluid resuscitation
(normal saline solution or lactated Ringer’s solution).
6. Medications appropriate for reaction type.
The ABCs of acute cardiopulmonary resuscitation,
assessment of airway, breathing, circulation, are of para-
mount importance when managing contrast reactions. After
the appropriate emergency response team has been called,
ensuring or establishing an airway and ventilating the patient
must be performed. Basic methods to ensure airway patency
include the head tilt-chin lift maneuver, suctioning, and an
oropharyngeal airway. Advanced airway adjuncts include
a laryngeal mask airway and endotracheal intubation [28].
Supplemental oxygen should be administered by mask at
a high rate (6-10 L/min). Hypoxia may complicate virtually
all emergencies that occur in a radiology department,
contrast or noncontrast related (eg, cardiac ischemia, vaso-
vagal event, seizure). Oxygen should be used for all patients
with moderate or severe reactions. Administration via nasal
prongs is much less effective than with a mask and should be
avoided if possible [5]. A history of chronic obstructive
pulmonary disease or emphysema is not a contraindication
for oxygen therapy in contrast reactions. In acute settings,
prevention of tissue hypoxia supersedes carbon dioxide
retention concerns in this patient group [29].
Once airway and ventilation have been managed, atten-
tion is then turned to the patient’s circulatory system.
Obtaining intravenous access with at least 2 large-bore IVs
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hypotension. Intravascular fluid resuscitation alone has been
reported to be the most effective treatment for hypotension
[30]. Elevating the patient’s legs 45 or more is a useful
adjunct, because this maneuver may increase central venous
return by up to 700 mL [31].
Mild reactions comprise the vast majority of acute contrast
reactions. If, upon the initial assessment, the patient has stable
vital signs with a secure airway, then the radiologist may
perform more detailed respiratory and skin evaluations
[1,5,10,17]. Talking with the patient will assess whether he or
she is short of breath or experiencing hoarseness, or has
excessive coughing [5,10]. Auscultation of the neck and chest
may reveal inspiratory stridor worrisome for laryngeal
oedema, expiratory wheezing consistent with bronchospasm,
or rales and/or crackles suggestive of pulmonary oedema. Skin
may be evaluated for hives, erythema, or oedema.
The patient’s overall demeanormay be helpful in narrowing
the differential diagnosis of adverse reactions. For example,
the uncomfortable but calm patient may have a cutaneous
reaction, with itching and hives. Observation alone or
diphenhydramine for symptomatic relief may be all that is
needed. The subdued or poorly responsive patient is likely
experiencing cardiovascular compromise, either in the form of
a vasovagal reaction or primary hypotension and diffuse
systemic vasodilation. The patient who is anxious or agitated is
likely experiencing respiratory compromise. Laryngeal
oedema and bronchospasm are of primary concern for this
patient group. Other, less likely, etiologies include pulmonary
oedema, hypertensive crisis, and anxiety reaction [1,10].Table 5
Recognition and treatment of acute contrast reactions in adultsa
Urticaria Observe the patient; diphenhydra
Bronchospasm Oxygen by mask (10 L/min); b-
terbutaline, or albuterol.
Laryngeal oedema Oxygen by mask (10 L/min).
Epinephrine If not hypotensive, then use 1:10
then 1:10,000, IV, 1 mL (0.1 m
EpiPen (0.3 mg) IM.
Anaphylaxis-like, generalized,
systemic reaction
Suction as needed; elevate the pa
IV fluids Normal saline solution or lactate
Epinephrine If not hypotensive, then use 1:10
subcutaneous epinephrine if th
1 mL (0.1 mg) given slowly I
maximum of 1 mg; if there is
then add b-2 agonist metered
or albuterol.
Hypotension Elevate the patient’s legs; oxyge
IV fluids Normal saline solution or lactate
administer epinephrine, 1:10,0
be obtained, then 1:1000, 0.3
Vagal reaction (hypotension
plus bradycardia)
Elevate the patient’s legs; oxyge
IV fluids Normal saline solution or lactate
Atropine 0.6-1.0 mg IV; repeat every 3-5
IM = intramuscular; IV = intravenous; PO = orally.
a From Ref. 10.
b Benadryl (McNeil Consumer Healthcare, Fort Washington, PA).
c EpiPen Jr (Dey Pharma, LP, Basking Ridge, NJ).Special Considerations in Pediatric Patients
The incidence of adverse contrast reactions in children is
rare and increases in frequency with advancing age. In
a large retrospective study by Callahan et al [32] performed
at an urban children’s hospital, the incidence of adverse
reaction to nonionic contrast media was 0.46% (57 of
12,4949 patients). The majority of these reactions (47 of 57)
were mild [32]. The most common reactions in pediatric
patients are cutaneous and respiratory in nature. Pediatric
patients increased susceptibility to respiratory reactions may
be due to small airway calibre and/or immature respiratory
musculature [1,6]. Reactions can be harder to detect in
children due to the inability to communicate symptoms.
Management of pediatric contrast reactions is similar to
management in adults but with age-appropriate medication
dosage (Table 6) [33].
Treatment of Specific Acute Contrast Reactions
The following section describes treatment guidelines for
specific reactions. These guidelines are summarized in
Table 5. Pediatric dosage modifications are listed in Table 6.Nausea and VomitingNausea and/or vomiting after contrast administration are
typically self-limited. It is recommended to keep these
patients under close observation for at least 30 minutes while
maintaining intravenous access [5]. Decubitus positioning inmine (Benadrylb), 25-50 mg PO/IM or 25 mg IV.
2 agonist metered dose inhaler (2-3 deep inhalations); eg, metaproterenol,
00, 0.3 mg subcutaneously or 0.3 mg IM (EpiPenc); if hypotensive,
g) slowly IV over 2-5 min; alternative if not severely hypotensive,
tient’s legs if hypotensive; oxygen by mask (10 L/min).
d Ringer’s solution.
00, 0.3 mg; subcutaneously or 0.3 mg IM (EpiPen); do not use
e patient is hypotensive; If the patient is hypotensive, then 1:10,000 IV,
V over 2-3 min, and incrementally repeat small doses as needed, up to
no IV access, then use EpiPen (0.3 mg) IM; if bronchospasm is prominent,
dose inhaler (2-3 deep inhalations), eg, metaproterenol, terbutaline,
n by mask (10 L/min).
d Ringer’s solution; if unresponsive, then call a code and begin to
00, IV, 1 mL (0.1 mg) slowly IV over 2-3 min; if IV access cannot
mg IM (EpiPen).
n by mask (10 L/min).
d Ringer’s solution.
min as needed, up to maximum of 3 mg.
Table 6
Pediatric dosage schedulesa
Medication Dose
Epinephrine
Subcutaneous (1:1000) 0.01 mL/kg (0.01 mg/kg), repeat in 15-30 min, maximum 0.3 mL/dose
Intravenous (1:10,000) 0.1 mL/kg (0.01 mg/kg), repeat every 5-15 min as necessary, give slowly and titrate to effect
Intramuscular (EpiPen Jrb) 0.15 mg
Atropine 0.02 mg/kg IV
Minimum initial dose, 0.1 mg
Maximum initial dose, 0.6 mg (infants and children), 1.0 mg (adolescents)
Maximum total dose 0.04 mg/kg, 1.0 mg (children), 2.0 mg (adolescents)
b-2 Agonist inhaler: Albuterol (Proventil,c Ventolind) Two puffs every 20-30 min, as necessary, 90-180 mg
H1 antihistamine: Diphenhydramine (Benadryle) 1-2 mg/kg IV or PO, up to maximum dose of 50 mg
IV ¼ intravenous; PO ¼ orally.
a From Ref. 1.
b EpiPen Jr (Dey Pharma, LP, Basking Ridge, NJ).
c Proventil (Merck, Whitehouse Station, NJ).
d Ventolin (GlaxoSmithKline, Brentford, United Kingdom).
e Benadryl (McNeil Consumer Healthcare, Fort Washington, PA).
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of aspiration. In refractory cases, antiemesis medications
may be administered intravenously [1,5].UrticariaPatients who experience urticaria are typically calm but
uncomfortable [6]. These responses are limited to the skin
and soft tissues. Local vasodilation causes erythema, and
capillary leakage causes the red raised skin wheal that is
characteristic of urticaria. Pruritus is the most common
symptom [1]. If urticaria manifests only as a few scattered
hives or mild pruritus, then treatment is generally not
necessary. If the cutaneous response is protracted, more
extensive in distribution, or particularly bothersome to the
patient, then therapy may be initiated. An H1 antihistamine
such as diphenhydramine (Benadryl; McNeil Consumer
Healthcare, Fort Washington, PA), 25-50 mg orally or 25 mg
intravenously in adult patients, often suffices [17].Vasovagal ReactionThe subdued or poorly responsive patient should be
suspected of having contrast-related hypotension [10].
Sinus bradycardia (pulse rate less than 60 beats per minute)
and hypotension (systolic blood pressure less than 80 mm
Hg) in the acute setting are classic manifestations of
a vasovagal reaction. Loss of consciousness may or may
not occur. The pathophysiology for this entity involves
a parasympathetic reflex activation that triggers a rapid
decrease in heartbeat and reduction in vascular tone [34].
Although it was previously believed to be the result of
cardiac mechanoreceptors, cerebral signal is now consid-
ered more probable [35].
Initial management for vasovagal reactions includes leg
elevation, intravenous fluid resuscitation, and oxygen by
mask. If the symptomatic bradycardia persists, then intra-
venous atropine may be administered. Atropine inhibits
vagal stimulation on the heart, which results in increasedchronotropy [36]. In the adult patient, 0.6-1.0 mg should be
administered intravenously, repeating if necessary after 3-5
minutes, to a maximum dose of 3 mg. In pediatric patients,
0.02 mg/kg should be administered intravenously (maximum
of 0.6 mg per dose), repeating as necessary after 3-5 minutes
to a maximum dose of 2 mg [5].Isolated HypotensionProfound hypotension without respiratory symptoms may
result after intravascular contrast administration. Either
normal sinus rhythm or compensatory tachycardia may
occur, in contradistinction to the bradycardia seen in vaso-
vagal reactions. Leg elevation and rapid intravenous fluid
resuscitation are critical for increasing central venous return
[30,31]. High-rate supplemental oxygen is also recom-
mended. If hypotension is recalcitrant to initial management,
then intravenous or intramuscular epinephrine is warranted
to facilitate vasoconstriction [37].BronchospasmThe hallmark of bronchospasm is expiratory wheezing on
chest auscultation, as in asthma. Bronchospasm without
cardiovascular findings is best treated with supplemental
oxygen and bronchodilator therapy. A b-2 agonist, such as
albuterol, may be administered via a metered-dose inhaler;
2-3 deep inhalations are typically performed [38]. For
moderate or severe bronchospasm that is refractory to
bronchodilator therapy, epinephrine may be used for its
generalized b-adrenergic stimulation [10].Laryngeal OedemaThis reaction involves angioedema of the upper aero-
digestive tract. Common presenting symptoms include new-
onset voice changes or hoarseness, cough, sensation of
a lump or tightness within the throat, and inspiratory stridor.
These patients are often anxious or agitated. Severe laryngeal
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necessitates rapid diagnosis and therapy [39]. This condition
does not respond well to bronchodilator therapy, and, in fact,
b-agonists may worsen the angioedema [1]. Intubation may be
difficult in these patients, which underscores the need for rapid
epinephrine administration. Please refer to section ‘‘Gener-
alized Anaphylactoid Reactions’’ for route and dosage
guidelines.Generalized Anaphylactoid ReactionsThese entities are rapidly progressive systemic reactions
characterized by multiorgan involvement. Possible manifes-
tations include angioedema, respiratory distress, pulmonary
oedema, hypotensive shock, and cardiac arrest [40]. When
a severe anaphylactoid reaction is suspected, it is critical to
get trained providers involved as early as possible. The
radiologist should have a low threshold to call for assistance
such as the rapid response team, emergency department, or
intensive care unit.
Airway management, oxygen by mask, leg elevation, and
intravenous fluids should be initiated immediately.
Epinephrine is the mainstay of therapy for generalized
anaphylactoid reactions. Epinephrine stimulates both a- and
b-adrenergic receptors [41]. With subcutaneous release,
intramuscular, or slow intravenous injection, the desirable
b-adrenergic effects predominate. Central b-agonist effects
augment both the strength and rate of cardiac contractions,
while peripherally there is bronchiolar relaxation [42].
Intravenous epinephrine therapy is often warranted for
severe anaphylactoid reactions: Epinephrine 0.1 mg (1 mL) of
1:10,000 concentration, given slowly over 2-5minutes in adult
patients; 0.01 mg/kg up to 0.1 mg per single dose of 1:10,000
concentration epinephrine in pediatric patients [1]. If only
1:1000 epinephrine is available, either dilution in normal
saline solution should be performed or one-tenth the above
volume should be administered. Dosing may be repeated as
needed. It should be stressed that the intravenous route puts the
patient at greater risk for harmful cardiovascular adverse
effects, and is best used by experienced providers [43].
Intramuscular administration of epinephrine is a viable
alternative to the intravenous route. Autoinjector intramus-
cular devices such as EpiPen and EpiPen Jr (Dey Pharma, LP,
Basking Ridge, NJ) deliver 0.3 mg and 0.15 mg to adult
patients and to pediatric patients, respectively. Epinephrine
autoinjectors have been increasingly used at many institutions
because they provide an easy-to-use, sterile, premeasured
single dose. The middle third of the thigh, usually the ante-
rolateral aspect, is the recommended administration site due to
easy accessibility and sufficient muscle bulk in this location.
Dosing may be repeated after 5 minutes if the patient’s
symptoms do not resolve [43e45].
Patients who have experienced a severe anaphylactoid
reaction should remain under close clinical observation for at
least 6 hours after treatment [43,46]. The incidence of
biphasic reactions ranges from 1%-20% in the literature [47].
Patients at greater risk for these recurrent reactions includethose with severe asthma, limited access to emergency health
facilities, and the possibility of continued allergen absorp-
tion. In these high-risk patients, close observation for up to
24 hours may be warranted [43,47].
The reader is directed to the American College of Radi-
ology Manual on Contrast Media, 7th edition, a Web-based
document published in 2010, which serves as an excellent
reference for all practicing radiologists regarding the safe use
of contrast media [48].Conclusion
The incidence of acute reactions to intravascular contrast
media fortunately is low. Low-osmolar iodinated agents are
generally well tolerated and preferred to high-osmolar
agents. The patients at highest risk for reaction include
those with prior reactions and those with asthma. Avoidance
of contrast media is the best form of prevention. For those
patients who need contrast but are at increased risk of
reaction, corticosteroid premedication regimens should be
applied. Initial evaluation includes calling for help, assessing
the patient, and taking vital signs, ensuring or establishing an
airway, ventilating with supplemental oxygen, and circula-
tory support. For the most-severe anaphylactoid reactions,
epinephrine is the medication of choice. Intramuscular and
intravenous administration are the preferred routes. Prompt
recognition of acute contrast reactions will facilitate treat-
ment and improve patient outcomes.References
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